SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, Inc., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today reported study findings on its drug candidate Homspera™. The results show Homspera to be effective in stimulating human, adult, blood-forming stem cells (hematopoietic stem cells), which have previously been shown to be capable of becoming blood cells that are vital to the body’s immune system. This suggests a role for Homspera in strengthening the human immune system.
